Lynx Also Announces Additional 2002 Speaking Engagements
HAYWARD, Calif., Jan. 8 /PRNewswire-FirstCall/ --
Lynx Therapeutics, Inc. (Nasdaq: LYNX) announced today that Dr. Norrie
Russell, President and Chief Executive Officer, will be presenting at the 20th
Annual JP Morgan H&Q Healthcare Conference in San Francisco, California on
Thursday, January 10, 2002 at 9:00 AM PST in the Elizabethan A&B Room at the
Westin St. Francis Hotel.
The presentation will be available on the Conference's website and be
accessible for sixty days. The website is:
http://www.eventsdigital.com/events/jpmhq/healthcare2002. The presentation will also
be available on the Lynx website at http://www.lynxgen.com.
Dr. John Wiktorowicz, Director of Proteomics at Lynx, will be speaking at
the Cambridge Healthtech Institute's Second Annual Human Proteome Project
Meeting. The event will take place from January 9-11, 2002 at the Hilton
Resort in San Diego, California. Dr. Wiktorowicz will be presenting Lynx's
Protein ProFiler(TM) proteomics technology on January 9, 2002 in a talk
titled, "A Novel Approach to Complex Proteomic Separations: High-Throughput
Liquid 2-D Electrophoresis." The conference will be used as an arena for the
leaders in the proteomics field to discuss the importance of identifying
proteins for study in various disease treatments. The institute's website is
http://www.healthtech.com.
Lynx is a corporate sponsor, booth exhibitor and presenter at the
Cambridge Healthtech Institute's Genome Tri-Conference 2002 to be held
February 23-March 1, 2002 at the Santa Clara Convention Center in Santa Clara,
California. In the Ninth Annual Human Genome Discovery-"Converting Disease
Biology into Tractable Targets" portion of the conference, Dr. Norrie Russell
is a Scientific Advisor and Dr. Ben Bowen, Lynx's Vice President, Discovery
Research, will present Lynx's Discovery Research efforts using Lynx's
Massively Parallel Signature Sequencing, or MPSS(TM), technology in a
presentation titled, "The Importance of Quantitative Gene Expression Analysis:
Getting to New Biology."
Other Lynx public speaking engagements for in the first quarter of 2002
include:
-- February 6-9, 2002
Conference: "Advances in Genome Biology and Technology"
(http://www.agbt.org)
Marco Island, Florida
Title: "Novel Approaches for Complex Trait Analysis"
Speaker: Ben Bowen, D. Phil., Vice President, Discovery
Research
-- February 11-12, 2002
Cambridge Healthtech Institute
Conference: "Gene Quantification: Introspection and RNA
Meditations"
San Diego, California
Title: "Megatype(TM) Technology for High-Throughput Genome-
Wide Scanning and Discovery of Trait/Disease-
Associated SNPs"
Speaker: Rongdian Fu, Senior Scientist
-- February 21-22, 2002
AgroGene (http://www.agrogene.com)
Conference: "Gene Expression and Proteomics"
Paris, France
Title: "Novel Approaches for Complex Trait Analysis"
Speaker: Ben Bowen, D. Phil., Vice President, Discovery
Research
Lynx is a leader in the development and application of novel technologies
for the discovery of gene expression patterns and genomic variations important
to the pharmaceutical, biotechnology and agricultural industries. These
technologies are based on the Megaclone(TM) technology, Lynx's unique and
proprietary cloning procedure, which transforms a sample containing millions
of DNA molecules into one made up of millions of micro-beads, each of which
carries approximately 100,000 copies of one of the DNA molecules in the
sample. Megaclone(TM) technology is the foundation for Lynx's analytical
applications, including: MPSS(TM) technology, which provides gene sequence
information and quantitative gene expression data; Megasort(TM) technology,
which provides differentially expressed gene sets; and Megatype(TM)
technology, which is expected to provide single nucleotide polymorphism, or
SNP, disease- or trait-association information. Lynx is also developing a
proteomics technology, Protein ProFiler(TM), which aims to provide high-
resolution analysis of complex mixtures of proteins from cells or tissues.
For more information, visit Lynx's web site at http://www.lynxgen.com.
This press release contains "forward-looking" statements, including
statements related to future presentations to be made by Lynx personnel. Any
statements contained in this press release that are not statements of
historical fact may be deemed to be forward-looking statements. Words such as
"believes," "anticipates," "plans," "predicts," "expects," "estimates,"
"intends," "will," "continue," "may," "potential," "should," "confident" and
similar expressions are intended to identify forward-looking statements. There
are a number of important factors that could cause the results of Lynx to
differ materially from those indicated by these forward-looking statements,
including, among others, risks detailed from time to time in the Company's SEC
reports, including its Annual Report on Form 10-K for the year ended December
31, 2000 and its most recent Quarterly Report on Form 10-Q. Lynx does not
undertake any obligation to update forward-looking statements.
SOURCE Lynx Therapeutics, Inc.
 back to top
Related links:
http://www.lynxgen.com
CONTACT:
Julio Cantre of Cohn & Wolfe Healthcare,
+1-212-798-9779, for Lynx Therapeutics, Inc.
|
